Laninamivir octanoate
Phase 2Small molecule
Laninamivir octanoate is one of 30 small molecule programs targeting Chronic Asthma. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Laninamivir octanoate
BBiota Scientific Management Pty Ltd
Phase 2
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Fluvirin
NovartisPreclinical
Diphtheria-Tetanus-Acellular Pertussis Vaccine
CanSino Biologics Inc.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Influenza2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Laninamivir octanoate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details